Jennifer Jaroscak MD
Medical Professor of Pediatrics, Pediatric Transplant and Cellular Therapy, Duke University Medical Center
Join to view full profile
2301 Erwin RoadDurham, NC 27705
Dr. Jaroscak is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jennifer Jaroscak is a Pediatric Hematology & Oncology specialist based in Durham, NC. She completed her fellowship in Pediatric Hematology/Oncology at the University of North Carolina Hospitals and her pediatric residency at Nationwide Children's Hospital/Ohio State University. Currently, she is involved in Pediatric Transplant and Cellular Therapy at Duke Children's Hospital and Health Center. Dr. Jaroscak's expertise includes hematopoietic stem cell transplantation, gene therapy, and pediatric bone marrow transplantation. Her published research has contributed to the understanding of treatments for sickle cell disease and pediatric CAR T-cell associated toxicities and has been cited by other works multiple times. She is also engaged in clinical trials focused on innovative treatments for severe sickle cell disease.
Education & Training
University of North Carolina HospitalsFellowship, Pediatric Hematology/Oncology, 1996 - 1999
Nationwide Children's Hospital/Ohio State UniversityResidency, Pediatrics, 1993 - 1996
Ohio State University College of MedicineClass of 1993
Certifications & Licensure
NC State Medical License 2025 - 2027
SC State Medical License 2010 - 2027- NC State Medical License 2025 - 2026
OH State Medical License 1994 - 2008
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation Start of enrollment: 2019 Mar 22
- A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) Start of enrollment: 2021 May 04
- Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy Start of enrollment: 2020 Oct 21
Publications & Presentations
PubMed
- 12 citationsHematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.Mark C Walters, Mary Eapen, Yiwen Liu, Fuad El Rassi, Edmund K Waller
Blood Advances. 2025-03-11 - 5 citationsLong-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.Mary Eapen, Jianqun Kou, Martin Andreansky, Monica Bhatia, Joel Brochstein
American Journal of Hematology. 2024-04-01 - 12 citationsRelationship between epa level of supervision with their associated subcompetency milestone levels in pediatric fellow assessment.Richard B Mink, Carol L Carraccio, Bruce E Herman, Pnina Weiss, David A Turner
BMC Medical Education. 2023-10-03
Press Mentions
Sickle Cell Success Stories: Why Spring Break Will Lead to a First for These TwoMarch 27th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: